Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P: Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 25:1033–1041, 2002

Figures 3 and 4 of the above-listed article were mistakenly switched. The correct figures and legends are shown below. Please disregard the original erratum published in Diabetes Care 25:1495, 2002.

Figure 3—

Fasting serum glucose levels over time with placebo (○) or 120 mg orlistat (•). P = 0.02, least-squares mean difference from placebo in the change from baseline over 52 weeks.

Figure 3—

Fasting serum glucose levels over time with placebo (○) or 120 mg orlistat (•). P = 0.02, least-squares mean difference from placebo in the change from baseline over 52 weeks.

Close modal
Figure 4—

HbA1c over 1 year of double-blind treatment with placebo (○) or 120 mg orlistat (•). P = 0.002, least-squares mean difference from placebo in the change from baseline over 52 weeks.

Figure 4—

HbA1c over 1 year of double-blind treatment with placebo (○) or 120 mg orlistat (•). P = 0.002, least-squares mean difference from placebo in the change from baseline over 52 weeks.

Close modal